Innate Pharma S.A. logo
Innate Pharma S.A. IPHA
$ 1.33 -2.92%

Annual report 2024
added 03-21-2026

report update icon

Innate Pharma S.A. EPS Ratio 2011-2026 | IPHA

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Innate Pharma S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - -0.66 -0.81 -0.31 0.05 -0.89 - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
0.05 -0.89 -0.524

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
-5.64 $ 14.21 -0.42 % $ 208 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
-1.77 - -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
1.51 - 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.51 - 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
-1 $ 3.35 -2.62 % $ 295 M usaUSA
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-8.28 $ 216.26 -0.83 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
2.1 $ 19.12 -0.57 % $ 894 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-0.36 - - $ 26.5 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
-1.45 $ 0.62 2.14 % $ 7.1 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
-13.7 - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-6.47 $ 46.45 -0.91 % $ 4.18 B schweizSchweiz
Acasti Pharma Acasti Pharma
ACST
-0.79 - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-1.66 - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
-7.99 - -9.65 % $ 45.9 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-15.8 - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-0.86 $ 1.4 -0.36 % $ 357 M britainBritain
Exelixis Exelixis
EXEL
2.88 $ 41.13 -0.69 % $ 11.2 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-2.46 - - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
-1.89 - - $ 3.74 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
-2.16 $ 2.63 - $ 16.5 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
-1.18 $ 6.64 -3.63 % $ 421 K usaUSA
Atreca Atreca
BCEL
-2.52 - -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
0.85 - -4.8 % $ 255 M usaUSA
Genmab A/S Genmab A/S
GMAB
34.4 $ 25.59 -0.35 % $ 16.5 B danmarkDanmark
Grifols, S.A. Grifols, S.A.
GRFS
0.28 $ 7.64 -0.72 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
Halozyme Therapeutics Halozyme Therapeutics
HALO
2.64 $ 61.68 -1.88 % $ 7.39 B usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
2.76 $ 26.99 -2.21 % $ 1.55 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-2.08 - -74.18 % $ 955 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
-0.26 $ 6.43 0.31 % $ 52.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
Immatics N.V. Immatics N.V.
IMTX
-4.77 $ 9.32 -2.0 % $ 586 M germanyGermany
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
-1.41 $ 69.48 -1.85 % $ 11.1 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-0.17 $ 4.29 -2.94 % $ 822 M canadaCanada
Akouos Akouos
AKUS
-2.52 - 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-2.38 - 1.93 % $ 17.4 M usaUSA